• Amazon for dental and medical practices.
• Grainger for healthcare supplies.
• Sysco for dental and medical offices.

• Dental Products: Distributes a comprehensive range of consumables, small equipment, and large equipment for dental practices worldwide.
• Dental Services: Provides practice management software, technical equipment repair, financial services, and digital dentistry solutions to dental professionals.
• Animal Health Products: Supplies pharmaceuticals, vaccines, diagnostic tests, and medical supplies for veterinary clinics and animal hospitals.
• Animal Health Services: Offers practice management software, business solutions, and technical support to veterinary practices.
• Medical Products: Provides medical-surgical supplies, vaccines, and pharmaceuticals to physician offices and outpatient clinics.
• Medical Services: Delivers practice management software and business services tailored for medical practitioners.

Henry Schein (symbol: HSIC) primarily sells to other companies and organizations, making it a business-to-business (B2B) model.

Due to the highly fragmented nature of the healthcare provider market that Henry Schein serves (with over 1 million customers globally), the company does not have a small number of individually named "major customer companies" that account for a significant portion of its revenue in the traditional sense. Instead, its major customers are broadly categorized by the types of healthcare businesses and institutions it serves.

The primary categories of customers that Henry Schein serves include:

• Dental Practices/Offices: This includes general dentists, orthodontists, oral surgeons, and other dental specialists.
• Medical Practices/Offices: Encompassing physicians' offices, specialty clinics, and other outpatient medical facilities.
• Laboratories: Both dental laboratories and medical diagnostic laboratories.
• Government and Institutional Healthcare Clinics: Such as hospitals, community health centers, and other government-managed healthcare facilities.

null

Stanley M. Bergman, Chairman of the Board and Chief Executive Officer

Stanley M. Bergman has served as Chairman of the Board and Chief Executive Officer of Henry Schein, Inc. since 1989, having joined the Company in 1980. He is a South African Chartered Accountant and a New York State Certified Public Accountant (CPA).

Ronald N. South, Senior Vice President and Chief Financial Officer

Ronald N. South was appointed Senior Vice President and Chief Financial Officer of Henry Schein, Inc. in April 2022. He joined the Company in 2008 as Vice President, Corporate Finance and Chief Accounting Officer. Prior to Henry Schein, Mr. South held various leadership roles at Bristol-Myers Squibb, including Vice President of Finance for Cardiovascular and Metabolic business lines, Vice President, Controller for the U.S. Pharmaceutical Division, and Vice President, Corporate General Auditor. He also served as Director-Corporate Audit at Pepsi-Cola Newburgh Bottling Co., Inc. and Vice President-Finance at Bristol-Myers Squibb Pharma Research Labs LLC.

Michael S. Ettinger, Executive Vice President and Chief Operating Officer

Michael S. Ettinger has been Executive Vice President and Chief Operating Officer of Henry Schein, Inc. since 2022, after joining the Company in 1994. His previous roles at Henry Schein include Senior Vice President, Corporate & Legal Affairs and Chief of Staff, Secretary (2015-2022), and prior to that, various positions including Corporate Senior Vice President, General Counsel & Secretary.

Mark E. Mlotek, Executive Vice President and Chief Strategic Officer

Mark E. Mlotek has served as Executive Vice President and Chief Strategic Officer since 2012, and has been with Henry Schein, Inc. since 1994. He previously held positions as Senior Vice President and Executive Vice President of the Corporate Business Development Group, and Vice President, General Counsel and Secretary. Before joining Henry Schein, Mr. Mlotek was a partner in Proskauer Rose from 1989 to 1994.

Andrea Albertini, Chief Executive Officer, Global Distribution and Technology

Andrea Albertini is the Chief Executive Officer, Global Distribution and Technology. He served as CEO, International Distribution Group from February 2023 to January 2025 and President, International Distribution Group from 2021 to February 2023. Before joining Henry Schein, he held leadership positions at Cefla and Castellini, both prominent global manufacturers of dental and medical equipment and instruments. He brings over 20 years of experience in the healthcare industry.

Addressable Markets for Henry Schein's Main Products and Services

Dental Market

The global dental market, which encompasses dental consumables, equipment, and other related products, was valued at approximately USD 39.66 billion in 2024. This market is projected to grow significantly, reaching an estimated USD 121.22 billion by 2034, with a compound annual growth rate (CAGR) of 11.82% from 2025 to 2034.

In North America, the dental market size was approximately USD 14.79 billion in 2024. Specifically, the U.S. dental market was valued at about USD 11.60 billion in 2024 and is anticipated to reach around USD 36.15 billion by 2034, demonstrating a CAGR of 12.02% from 2025 to 2034.

Healthcare Distribution Market (Medical Products and Services)

Henry Schein's medical segment is part of the broader healthcare distribution market, which includes the distribution of pharmaceuticals, medical devices, equipment, and supplies. The global healthcare distribution market is estimated to be approximately USD 1.19 trillion in 2025 and is projected to reach around USD 2.20 trillion by 2034, growing at a CAGR of 7.08% from 2025 to 2034.

For North America, the healthcare distribution market size surpassed USD 480 billion in 2024. The U.S. healthcare distribution market was valued at USD 330 billion in 2024 and is expected to reach approximately USD 670 billion by 2034, with a CAGR of 7.34% from 2025 to 2034.

Henry Schein, Inc. (HSIC) is expected to drive future revenue growth over the next two to three years through several strategic initiatives and market dynamics:

1. Execution of the BOLD+1 Strategic Plan and Value Creation Initiatives: Henry Schein's BOLD+1 Strategic Plan is a core driver, aiming to accelerate growth and expand margins by focusing on high-growth, high-margin businesses and enhancing digital capabilities. This strategy is anticipated to deliver over $200 million in operating income improvement over the coming years through initiatives like centralizing support services, optimizing indirect procurement, and automating processes.
2. Growth in Digital Solutions and Technology: The company's Global Technology Group has shown remarkable sales growth, significantly driven by a substantial increase in customers for cloud-based practice management solutions. Henry Schein is strategically investing in artificial intelligence (AI) and digital solutions, including the phased rollout of a new global eCommerce platform, which is expected to further accelerate recurring Software-as-a-Service (SaaS) revenue and client retention.
3. Strategic Acquisitions, Particularly in the Home Medical Supplies Market: Henry Schein is actively expanding its reach through strategic acquisitions, notably in the home medical supplies market. The January 2025 acquisition of Acentus, a specialist in Continuous Glucose Monitors, highlights this focus, projected to increase the annual revenue in this segment to over $350 million. This follows previous strategic investments in homecare, reinforcing a sustained commitment to this growing market.
4. Market Share Gains in Distribution Businesses: Following the resolution of a cyber incident, Henry Schein has reported accelerating sales growth across all reportable segments, including solid market share gains in its distribution businesses. This renewed focus on driving growth in its core distribution segments is a significant contributor to the company's overall revenue trajectory.

Share Repurchases

• Henry Schein repurchased approximately 3.3 million shares of common stock for a total of $229 million during the third quarter of 2025.
• As of the end of the third quarter of 2025, the company had $980 million authorized and available for future share repurchases, including a $750 million increase authorized by the Board of Directors in September 2025.
• During the second quarter of 2025, the company repurchased approximately 3.7 million shares for $259 million, which included $223 million under a previously announced Accelerated Stock Repurchase (ASR) plan.

Share Issuance

• In January 2025, Henry Schein issued new shares of common stock to funds affiliated with KKR for a strategic investment of $250 million.

Inbound Investments

• KKR made a $250 million strategic investment in Henry Schein's common stock, which was completed in May 2025, resulting in KKR holding approximately 12% of the common shares.
• The agreement provides KKR with the right to increase its ownership up to 19.9% through open market purchases.
• As part of the investment, two KKR representatives joined Henry Schein's Board of Directors to collaborate on value creation opportunities, strategic growth, operational excellence, and capital allocation.

Outbound Investments

• Henry Schein completed the acquisition of Acentus, a distributor of continuous glucose monitors, in November 2024.
• Other recent acquisitions include abc dental in July 2024 and TriMed in December 2023.
• The company's acquisition strategy is characterized by bolt-on transactions, often with privately held companies, to expand high-growth software, specialty, and services businesses.

Capital Expenditures

• Capital allocation priorities include driving organic growth, expanding operating margins, focusing on operational efficiency, and digital commerce.
• Strategic investments are being made in cloud-based platforms and AI solutions to accelerate recurring Software-as-a-Service (SaaS) revenue and client retention.
• Henry Schein is rolling out a phased launch of its Global eCommerce Platform in North America, following successful deployment in the UK and Ireland.